Current Medical Treatment for Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Incont Pelvic Floor Dysfunct 2007; 1(Suppl 2):15-19

Chieh-Lung Chou, M.D. Department of Urology, China Medical University Hospital, Taichung, Taiwan

fkqolar`qflk íêìëçê=ÅçìäÇ=ÄÉ=êÉëéçåëáÄäÉ=Ñçê=íÜÉ=áêêáí~íáîÉ=ëóãéíçãë=~ëëçÅá~íÉÇ=ïáíÜ _meK=píìÇáÉë=~êÉ=éêÉëÉåíäó=ìåÇÉêï~ó=íç=ÇÉíÉêãáåÉ=áÑ=ÜÉíÉêçÖÉåÉáíó=çÑ _ÉåáÖå=éêçëí~íáÅ=ÜóéÉêéä~ëá~=E_meF=áë=Åçããçå=~ãçåÖ=ãÉå=çîÉê ÇÉíêìëçê=êÉëéçåëáîÉåÉëë=íç=ëóãé~íÜçãáãÉíáÅë=~äëç=çÅÅìêë=áå=íÜÉ=ÜìJ RM=óÉ~êë=çÑ=~ÖÉK=fí=Ü~ë=~=åÉÖ~íáîÉ=áãé~Åí=çå=èì~äáíó=çÑ=äáÑÉ=EnçiF=~åÇ ã~å=Ää~ÇÇÉê=xQzK êÉÇìÅÉë=íÜÉ=ëÉåëÉ=çÑ=ïÉää=ÄÉáåÖK=içïÉê=ìêáå~êó=íê~Åí=ëóãéíçãë=EirqpF áåÅäìÇÉ=ìêáå~êó=ÑêÉèìÉåÅóI=ìêÖÉåÅóI=ïÉ~â=ëíêÉ~ã=~åÇ=åçÅíìêá~I=~åÇ `roobkq=αJ^aobkbodf`=^kq^dlkfpq=aordp=clo=qeb ~êÉ=Åçããçå=áå=ÉäÇÉêäó=ãÉå=~åÇ=Ü~îÉ=~=åÉÖ~íáîÉ=áãé~Åí=çå=nçiK=irqp qob^qjbkq=lc=_me ~êÉ=ìëì~ääó=~ëëçÅá~íÉÇ=ïáíÜ=_me=xNzK=oÉÅÉåíäóI=ëáÖåáÑáÅ~åí=éêçÖêÉëë=Ü~ë ÄÉÉå=ã~ÇÉ=áå=íÜÉ=ãÉÇáÅ~ä=ã~å~ÖÉãÉåí=çÑ=_meK=få=íÜáë=~êíáÅäÉI=ïÉ=êÉJ Non-selective drugs îáÉï=íÜÉ=ÅìêêÉåí=éÜ~êã~ÅçäçÖáÅ~ä=íêÉ~íãÉåí=çÑ=_meLirqpK =mÜÉåçñóÄÉåò~ãáåÉ=~åÇ=qÜóãçñ~ãáåÉ

αJ^aobkbodf`=_il`hbop Selective drugs

αN αJ^ÇêÉåÉêÖáÅ=ÄäçÅâÉêë=~êÉ=íÜÉ=ãçëí=Åçããçåäó=ìëÉÇ=ãÉÇáÅ~ä=íêÉ~íJ =pÜçêí=~ÅíáåÖW=fo=^äÑìòçëáåI=fåÇçê~ãáåI=mê~òçëáå ãÉåí=Ñçê=_meK=_me=Ü~ë=O=éÜóëáçäçÖáÅ~ä=ÅçãéçåÉåíëW=~=ëí~íáÅ=ÅçãéçJ =içåÖ=~ÅíáåÖW=po=^äÑìòçëáåI=açñ~òçëáåI=q~ãëìä~ëáåI=qÉê~òçëáå=xRz åÉåí=êÉä~íÉÇ=íç=áåÅêÉ~ëÉÇ=éêçëí~íÉ=ëáòÉ=~åÇ=~=Çóå~ãáÅ=ÅçãéçåÉåí=êÉJ ä~íÉÇ=íç=áåÅêÉ~ëÉÇ=éêçëí~íÉ=ëãççíÜ=ãìëÅäÉ=íçåÉK= J^ÇêÉåçÅÉéíçêë αN Phenoxybenzamine ã~áåí~áå=éêçëí~íÉ=ëãççíÜ=ãìëÅäÉ=íçåÉK= J^ÇêÉåçêÉÅÉéíçê=~åí~Öçåáëíë mÜÉåçñóÄÉåò~ãáåÉ=áë=~=åçåëÉäÉÅíáîÉ= =ÄäçÅâÉêI=~åÇ=Ü~ë=ÄÉÉå αN α ~Åí=çå=éêçëí~íÉ=~åÇ=ìêÉíÜê~ä=ëãççíÜ=ãìëÅäÉ=íç=êÉÇìÅÉ=íÜÉ=Çóå~ãáÅ ëÜçïå=íç=áãéêçîÉ=ëóãéíçãë=~åÇ=ã~ñáãìã=ìêáå~êó=Ñäçï=ê~íÉ=xSzK=aìÉ ÅçãéçåÉåí=çÑ=ìêÉíÜê~ä=êÉëáëí~åÅÉ=~åÇ=íÜìë=~ääÉîá~íÉ=îçáÇáåÖ=ëóãéíçãë íç=~=ÜáÖÜ=áåÅáÇÉåÅÉ=~åÇ=ëÉîÉêáíó=çÑ=~ÇîÉêëÉ=ÉîÉåíëI=íÜÉ=ÅäáåáÅ~ä=~ééäáJ xOzK=αJ^ÇêÉåÉêÖáÅ=ÄäçÅâÉêë=êÉäáÉîÉ=åçí=çåäó=çÄëíêìÅíáîÉ=Äìí=áêêáí~íáîÉ Å~íáçå=çÑ=éÜÉåçñóÄÉåò~ãáåÉ=áë=äáãáíÉÇK ëóãéíçãë=áå=é~íáÉåíë=ïáíÜ=_meI=~äíÜçìÖÜ=íÜÉ=ìåÇÉêäóáåÖ=ãÉÅÜ~åáëãë çÑ=íÜÉ=êÉäáÉÑ=çÑ=áêêáí~íáîÉ=ëóãéíçãë=~êÉ=ëíáää=ìåâåçïåK=`Ü~ééäÉ=Éí=~ä=Éî~äìJ Prazosin ~íÉÇ=NPR=é~íáÉåíë=ïáíÜ=ëóãéíçã~íáÅ=ìêçÇóå~ãáÅ~ääóJÅçåÑáêãÉÇ=çÄëíêìÅJ mê~òçëáå=áë=~=îÉêó=éçíÉåí=~åÇ=ëÉäÉÅíáîÉ= J~ÇêÉåÉêÖáÅ=~åí~ÖçåáëíK αN íáîÉ=_me=íêÉ~íÉÇ=Ñçê=NO=ïÉÉâë=ïáíÜ=ÉáíÜÉê=Ççñ~òçëáå=EST=é~íáÉåíëF=çê fíë=~ÑÑáåáíó=Ñçê=íÜÉ= JêÉÅÉéíçê=áë=NMMMJÑçäÇ=ÖêÉ~íÉê=íÜ~å=íÜ~í=Ñçê=íÜÉ= J αN αO éä~ÅÉÄç=ESU=é~íáÉåíëF=~ÑíÉê=~å=áåáíá~ä=O=ïÉÉâ=Ä~ëÉäáåÉ=Éî~äì~íáçåK=qïÉäîÉ êÉÅÉéíçêK=qÜÉ=ãçëí=áãéçêí~åí=~ÇîÉêëÉ=ÉÑÑÉÅí=çÑ=éê~òçëáå=áë=éçëíìê~ä ïÉÉâë=çÑ=íÜÉê~éó=ïáíÜ=Ççñ~òçëáå=êÉëìäíÉÇ=áå=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåíë ÜóéçíÉåëáçåI=~äíÜçìÖÜ=ëíìÑÑó=åçëÉI=ÜÉ~Ç~ÅÜÉ=~åÇ=êÉíêçÖê~ÇÉ=Éà~Åìä~J áå=ÜÉëáí~åÅóI=áãé~áêÉÇ=ìêáå~êó=ëíêÉ~ãI=åçÅíìêá~=~åÇ=ìêÖÉåÅóK=cêÉèìÉåÅó íáçå=ã~ó=~äëç=çÅÅìê=xTzK=`çåíáåìçìë=ìëÉ=Ñçê=~=äçåÖ=éÉêáçÇ=ÇÉÅêÉ~ëÉë áãéêçîÉÇ=ïáíÜ=Ççñ~òçëáå=íÜÉê~éó=xPzK=qÜÉ=ëíìÇó=éêçîÉÇ=íÜ~í=~å=α ÉÑÑáÅ~Åó=ÇìÉ=íç=í~ÅÜóéÜóä~ñáë=çê=~=éêçÖêÉëëáîÉ=áåÅêÉ~ëÉ=áå=éêçëí~íÉ ÄäçÅâÉê=áë=ÉÑÑÉÅíáîÉ=áå=êÉäáÉîáåÖ=ÄçíÜ=çÄëíêìÅíáçå=~åÇ=áêêáí~íáîÉ=ëóãéíçãëK ëáòÉ=~åÇI=ÜÉåÅÉI=êÉèìáêÉë=áåÅêÉ~ëÉ=áå=Ççë~ÖÉ=xUIVzK qÜÉ=êçäÉ=çÑ=íÜÉ=ëóãé~íÜÉíáÅ=åÉêîçìë=ëóëíÉã=áå=ÇÉíêìëçê=ÑìåÅíáçå=áë ëíáää=ìåÅäÉ~êK=`Üçì=Éí=~ä=ã~ééÉÇ=íÜÉ=êÉÖáçå~ä=ÇáëíêáÄìíáçå=çÑ== =~åÇ= J αN β Alfuzosin ~ÇêÉåÉêÖáÅ=êÉÅÉéíçêë=EôëF=áå=ê~ÄÄáí=îÉåíê~ä=~åÇ=Ççêë~ä=Ää~ÇÇÉêI=~åÇ ^äÑìòçëáå=áë=~=èìáåçòçäáåÉJÄ~ëÉÇ= JêÉÅÉéíçê=~åí~Öçåáëí=ïáíÜ=ëáãáJ αN ÅÜ~ê~ÅíÉêáòÉÇ=íÜÉ= Jô=ëìÄíóéÉë=êÉëéçåëáÄäÉ=Ñçê=åçêÉéáåÉéÜêáåÉ=áåJ ä~ê=~ÑÑáåáíó=íç=~ää= JêÉÅÉéíçê=ëìÄíóéÉëK=fí=Ü~ë=ÄÉÉå=ìëÉÇ=ÉñíÉåëáîÉäó=áå αN αN ÇìÅÉÇ=Åçåíê~Åíáçå=çÑ=ê~ÄÄáí=Ççêë~ä=ÇÉíêìëçê=ëãççíÜ=ãìëÅäÉK=`Üçì=Éí=~ä íêÉ~íáåÖ=_me=xNMINNzK=aÉ=kìåòáç=Éí=~ä=~å~äóòÉÇ=íÜÉ=ÅäáåáÅ~ä=~åÇ=OQJÜçìê ÑçìåÇ=êÉëéçåëÉë=íç=~ÇêÉåÉêÖáÅ=ëíáãìä~íáçå=áåÅäìÇÉÇW=ENF=íÜÉ=Ççêë~ä=~åÇ ìêáå~êó=Ñäçï=ÉÑÑáÅ~Åó=çÑ=~äÑìòçëáå=NM=ãÖ=çåÅÉ=Ç~áäóI=Äó=ãÉ~åë=çÑ=íÜÉ îÉåíê~ä=ÇçãÉI=ïÜÉêÉ=βJôë=éêÉÇçãáå~íÉI=EOF=íÜÉ=îÉåíê~ä=ÇÉíêìëçêI=ïÜÉêÉ fåíÉêå~íáçå~ä=mêçëí~íÉ=póãéíçã=pÅçêÉ=EfJmppF=~åÇ=ÜçãÉJÄ~ëÉÇ Jôë=éêÉÇçãáå~íÉI=EPF=íÜÉ=Ççêë~ä=ÇÉíêìëçêI=ïÜÉêÉ= Jôë=éêÉÇçãáå~íÉI ìêçÑäçïãÉíêó=EmJcäçïF=ãÉ~ëìêÉãÉåíI=áå=é~íáÉåíë=ïáíÜ=irqp=êÉä~íÉÇ=íç β αN ~åÇ=EQF=íÜÉ=Ççêë~ä=~åÇ=îÉåíê~ä=Ää~ÇÇÉê=åÉÅâI=ïÜÉêÉ= Jôë=éêÉÇçãáå~íÉK _meK=lîÉê~ääI=POU=ìêáå~êó=Ñäçïë=ïÉêÉ=êÉÅçêÇÉÇ=~åÇ=Éî~äì~íÉÇI=ïáíÜ=~å αN qÜÉ=~ìíÜçêë=ãÉåíáçåÉÇ=~=éêÉÇçãáå~åÅÉ=çÑ= Jô=áå=Üìã~å=Ççêë~ä=ÇÉJ ~îÉê~ÖÉ=çÑ=OT=Ñäçïë=éÉê=é~íáÉåíK=^=ëí~íáëíáÅ~ääó=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåí αN ï~ë=çÄëÉêîÉÇ=áå=ãÉ~å=ã~ñáãìã=Ñäçï=~åÇ=ìêáå~êó=îçáÇáåÖ=îçäìãÉK=qÜÉó ÅçåÅäìÇÉÇ=íÜ~í=íÜÉ=~äÑìòçëáå=NM=ãÖ=çåÅÉ=Ç~áäó=Ççë~ÖÉ=ëÜçïÉÇ=~=ëáÖJ Received: July 31, 2007 Accepted:August 11, 2007 åáÑáÅ~åí=áãéêçîÉãÉåí=áå=fJmpp=~ë=ïÉää=~ë=~=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåí=áå Address correspondence to: Dr. Chieh-Lung Chou, Department of Urology, China Medical ìêáå~êó=Ñäçï=é~ê~ãÉíÉêë=Enã~ñ=~åÇ=ìêáå~êó=îçáÇáåÖ=îçäìãÉF=ä~ëíáåÖ=Ñçê University Hospital, 2, Yu-Der Road, Taichung, Taiwan E-mail: ericchou [email protected] OQ=Üçìêë=áå=é~íáÉåíë=ïáíÜ=irqp=xNOzK

NR C. L. Chou

ôë=ãÉÇá~íÉ=~Åíáçåë=çÑ=åçêÉéáåÉéÜêáåÉ=~åÇ=ÉéáåÉéÜêáåÉ=íÜêçìÖÜ Terazosin αN qÉê~òçëáå=áë=íÜÉ=ãçëí=ÉñíÉåëáîÉäó=áåîÉëíáÖ~íÉÇ= =ÄäçÅâÉê=Ñçê=_meK íÜêÉÉ= ô=ëìÄíóéÉë=E I= =~åÇ= F=xOPzK=kçåëìÄíóéÉ=ëÉäÉÅíáîÉ αN αN αN^ αN_ αNa fí=Ü~ë=ÜáÖÜ=ëéÉÅáÑáÅáíó=Ñçê=íÜÉ= JêÉÅÉéíçê=~åÇ=ï~ë=çêáÖáå~ääó=ÇÉîÉäçéÉÇ ô=~åí~Öçåáëíë=êÉä~ñ=éêçëí~íÉ=ëãççíÜ=ãìëÅäÉI=~åÇ=êÉäáÉîÉ=çÄëíêìÅJ αN αN Ñçê=íÜÉ=íêÉ~íãÉåí=çÑ=ÜóéÉêíÉåëáçåK=fíë=Ü~äÑJäáÑÉ=áë=äçåÖÉê=íÜ~å=íÜ~í=çÑ íáîÉ=~åÇ=áêêáí~íáîÉ=ëóãéíçãë=xOQJOTzK=mêçëí~íÉ=ëãççíÜ=ãìëÅäÉ=êÉä~ñJ éê~òçëáå=~åÇ=áí=Å~å=ÄÉ=ÖáîÉå=çåÅÉ=~=Ç~ó=xNPzK=låäó=~Äçìí=NMB=çÑ ~íáçå=áë=ãÉÇá~íÉÇ=Äó= ô=xOUz=~åÇ=ÅçåëÉèìÉåíäó=ëìÄíóéÉ=ëÉäÉÅíáîÉ αN^ íÉê~òçëáå=áë=ÉñÅêÉíÉÇ=ìåÅÜ~åÖÉÇ=áå=íÜÉ=ìêáåÉK=açëÉë=çÑ=NM=ãÖLÇ=ã~ó ô=~åí~Öçåáëíë=áåÅêÉ~ëÉ=ìêáåÉ=Ñäçï=áå=_me=xOVzK=eçïÉîÉêI= ô αN^ αN^ ÄÉ=êÉèìáêÉÇ=Ñçê=ã~ñáã~ä=ÉÑÑÉÅí=çå=_me=xNQzK=qÉê~òçëáå=íÜÉê~éó=ÇçÉë ~åí~Öçåáëíë=Çç=åçí=~ééÉ~ê=íç=êÉäáÉîÉ=áêêáí~íáîÉ=ëóãéíçãë=xOVzK=dì=Éí=~ä åçí=~ÑÑÉÅí=ÄäççÇ=éêÉëëìêÉ=Åçåíêçä=áå=é~íáÉåíë=êÉÅÉáîáåÖ=ÅçåÅìêêÉåí=~åíáJ áåîÉëíáÖ~íÉÇ=íÜÉ=ÉÑÑÉÅí=çÑ=íÜÉ== ô=~åí~Öçåáëí=RJãÉíÜóä=ìê~éáÇáä=ERjrF αN^ ÜóéÉêíÉåëáîÉ=ãÉÇáÅ~íáçå=xNRINSzK îë=íÜÉ= ô=~åí~Öçåáëí=í~ãëìäçëáå=çå=ìêáå~êó=ÑêÉèìÉåÅó=áå=çÄëíêìÅíÉÇ αN^LNa ^=ãìäíáÅÉåíÉêI=ÇçìÄäÉJÄäáåÇI=ê~åÇçãáòÉÇI=éä~ÅÉÄçJÅçåíêçääÉÇ=ëíìÇó ê~íëK=qÜÉó=ÑçìåÇ=íÜ~í=ìêáå~êó=ÑêÉèìÉåÅó=áë=áåÅêÉ~ëÉÇ=áå=ê~íë=ïáíÜ=~=Ää~ÇJ çÑ=çåÅÉJ~JÇ~ó=íÉê~òçëáå=íç=é~íáÉåíë=ïáíÜ=ëóãéíçã~íáÅ=_me=ï~ë=ÅçåJ ÇÉê=ã~ëë=ÖêÉ~íÉê=íÜ~å=RMM=ãÖK=qÜÉ=ÅçãÄáåÉÇ= ô=~åí~Öçåáëí αN^LNa ÇìÅíÉÇ=Äó=iÉéçê=~åÇ=~ëëçÅá~íÉë=xNTzK=lÑ=íÜÉ=é~íáÉåíëI=OPT=ÅçãéäÉíÉÇ í~ãëìäçëáå=ÇÉÅêÉ~ëÉë=ìêáå~êó=ÑêÉèìÉåÅó=ãçêÉ=íÜ~å=íÜÉ= ô=ëÉäÉÅJ αN^ íÜÉ=QJïÉÉâ=ëáåÖäÉJÄäáåÇ=éä~ÅÉÄç=äÉ~ÇJáå=~åÇ=NOJïÉÉâ=ÇçìÄäÉJÄäáåÇ=íêÉ~íJ íáîÉ=~åí~Öçåáëí=Rjr=xPMzK=qÜáë=ÑáåÇáåÖ=ëìééçêíë=íÜÉ=ÜóéçíÜÉëáë=íÜ~í ãÉåí=éÉêáçÇëK=qÜÉ=NM=ãÖ=íÉê~òçëáå=Öêçìé=ÉñÜáÄáíÉÇ=ëáÖåáÑáÅ~åíäó=ÖêÉ~íÉê ô=áë=áãéçêí~åí=Ñçê=ãÉÇá~íáåÖ=áêêáí~íáîÉ=ëóãéíçãëK αNa áåÅêÉ~ëÉë=áå=éÉ~â=~åÇ=ãÉ~å=ìêáå~êó=Ñäçï=ê~íÉë=íÜ~å=íÜÉ=éä~ÅÉÄç=ÖêçìéK qÜÉ=~ìíÜçêë=ëí~íÉÇ=íÜÉáê=ëíìÇó=ÇÉãçåëíê~íÉë=íÜÉ=ë~ÑÉíó=~åÇ=ÉÑÑáÅ~Åó=çÑ RαJobar`q^pb=fkef_fqlop=E^kaoldbk=prmmobppflkF íÉê~òçëáå=Ñçê=íÜÉ=íêÉ~íãÉåí=çÑ=_meK ^åÇêçÖÉåë=~êÉ=êÉëéçåëáÄäÉ=Ñçê=éêçëí~íÉ=ÖêçïíÜ=~åÇ=ã~áåíÉå~åÅÉK Doxazosin qÜÉ=ÇÉéêáî~íáçå=çÑ=~åÇêçÖÉå=ÇÉÅêÉ~ëÉë=íÜÉ=ëáòÉ=çÑ=íÜÉ=éêçëí~íÉ=~åÇ iáâÉ=íÉê~òçëáåI=Ççñ~òçëáå=áë=~=ëÉäÉÅíáîÉ=αJ~ÇêÉåÉêÖáÅ=~åí~Öçåáëí êÉëáëí~åÅÉ=íç=çìíÑäçï=íÜêçìÖÜ=íÜÉ=éêçëí~íáÅ=ìêÉíÜê~I=~åÇ=íÜÉå=áãéêçîÉë çêáÖáå~ääó=ÇÉîÉäçéÉÇ=~ë=~å=~åíáÜóéÉêíÉåëáîÉ=xNUzK=açñ~òçëáå=ëÜçìäÇ=ÄÉ íÜÉ=~Äáäáíó=íç=ìêáå~íÉK=qÜÉ=ÇÉëáÖå=~åÇ=ÅÜÉãáëíêó=çÑ=RαJêÉÇìÅí~ëÉ=áåÜáÄáJ ÖáîÉå=áåáíá~ääó=~í=~=Ççë~ÖÉ=çÑ=N=ãÖLÇ=~åÇ=íáíê~íÉÇ=çîÉê=~=éÉêáçÇ=çÑ=NJO íçêë=Ü~ë=ÄÉÉå=íÜçêçìÖÜäó=ëíìÇáÉÇ=~åÇ=êÉîáÉïÉÇ=xPNzK=qïç=RαJêÉÇìÅJ ïÉÉâë=íç=~=ã~ñáãìã=ÇçëÉ=çÑ=U=ãÖLÇK=qáíê~íáçå=êÉÇìÅÉë=íÜÉ=êáëâ=çÑ=Ñáêëí í~ëÉ=áåÜáÄáíçêë=EÑáå~ëíÉêáÇÉ=~åÇ=Çìí~ëíÉêáÇÉF=~êÉ=åçï=~ééêçîÉÇ=Ñçê=ÜìJ ÇçëÉ=Å~êÇáçî~ëÅìä~ê=ÉÑÑÉÅíë=xTzK ã~å=ìëÉK açñ~òçëáå=d~ëíêçáåíÉëíáå~ä=qÜÉê~éÉìíáÅ=póëíÉã=EdfqpF=áë=~=åÉï ÅçåíêçääÉÇJêÉäÉ~ëÉ=Ñçêãìä~íáçåK=fí=Ü~ë=~å=~äíÉêÉÇ=éÜ~êã~ÅçâáåÉíáÅ=éêçÑáäÉI Finasteride ïÜáÅÜ=~ääçïë=~=ÜáÖÜÉê=áåáíá~ä=Ççë~ÖÉ=íç=ÄÉ=ìëÉÇ=íÜ~å=ïáíÜ=íÜÉ=ëí~åÇ~êÇ cáå~ëíÉêáÇÉ=ï~ë=íÜÉ=Ñáêëí=çåÉ=~ééêçîÉÇ=Ñçê=ìëÉ=Äó=íÜÉ=cççÇ=~åÇ Ñçêãìä~íáçå=~åÇ=äÉëë=íáíê~íáçå=ëíÉéë=íç=êÉ~ÅÜ=~=ÅäáåáÅ~ääó=ÉÑÑÉÅíáîÉ=ÇçëJ aêìÖ=^Çãáåáëíê~íáçå=Eca^F=Ñçê=íêÉ~íãÉåí=çÑ=_meK=cáå~ëíÉêáÇÉ=áåÜáÄáíë ~ÖÉ=xNVzK=^åÇÉêëçå=Éí=~ä=ÅçåÇìÅíÉÇ=~=ëíìÇó=íç=~ëëÉëë=íÜÉ=ÉÑÑÉÅíë=çÑ íÜÉ=íóéÉ=O=áëçÉåòóãÉ=çÑ=RαJêÉÇìÅí~ëÉI=ïÜáÅÜ=áë=éêÉëÉåí=áå=ÜáÖÜ=äÉîÉäë Ççñ~òçëáå=dfqp=Q=çê=U=ãÖ=çåÅÉ=Ç~áäóI=Ççñ~òçëáå=ëí~åÇ~êÇ=N=ãÖ=íç=U áå=íÜÉ=éêçëí~íÉK=qÜÉ=ÇÉÑáåáíáîÉ=ãìäíáÅÉåíÉê=íêá~ä=ï~ë=éÉêÑçêãÉÇ=Äó=íÜÉ ãÖ=çåÅÉ=Ç~áäóI=~åÇ=éä~ÅÉÄçI=áå=TVR=ãÉå=ïáíÜ=_meK=_çíÜ=Ççñ~òçëáå mibpp=Ecáå~ëíÉêáÇÉ=içåÖJqÉêã=bÑÑáÅ~Åó=~åÇ=p~ÑÉíó=píìÇó=ÖêçìéF=~åÇ dfqp=~åÇ=Ççñ~òçëáå=ëí~åÇ~êÇ=ëáÖåáÑáÅ~åíäó=áãéêçîÉÇ=íÜÉ=ëóãéíçãë=çÑ ï~ë=êÉéçêíÉÇ=áå=NVVU=xPOzK=^í=íÜÉ=ÉåÇ=çÑ=íÜÉ=ëíìÇóI=é~íáÉåíë=íêÉ~íÉÇ _meI=ïáíÜ=~=ÖêÉ~íÉê=áãéêçîÉãÉåí=çÄëÉêîÉÇ=É~êäáÉê=ÑçääçïáåÖ=íêÉ~íãÉåí ïáíÜ=Ñáå~ëíÉêáÇÉ=Ü~Ç=~=ëáÖåáÑáÅ~åíäó=ÜáÖÜÉê=ÇÉÅêÉ~ëÉ=áå=^ãÉêáÅ~å=rêçJ ïáíÜ=Ççñ~òçëáå=dfqp=íÜ~å=ïáíÜ=Ççñ~òçëáå=ëí~åÇ~êÇK=qÜÉ=çîÉê~ää=áåÅáJ äçÖáÅ~ä=^ëëçÅá~íáçå=póãéíçã=pÅçêÉ=E^r^ppF=~åÇ=~=ëáÖåáÑáÅ~åíäó=ÜáÖÜÉê ÇÉåÅÉ=çÑ=~ÇîÉêëÉ=ÉîÉåíë=ï~ë=ëáãáä~ê=~ãçåÖ=é~íáÉåíë=íêÉ~íÉÇ=ïáíÜ áåÅêÉ~ëÉ=áå=nã~ñ=Åçãé~êÉÇ=ïáíÜ=éä~ÅÉÄçK=mêçëí~íÉ=îçäìãÉ=~äëç=ÇÉJ Ççñ~òçëáå=dfqp=~åÇ=éä~ÅÉÄçI=~åÇ=ëäáÖÜíäó=ÜáÖÜÉê=áå=íÜçëÉ=çå=Ççñ~òçëáå ÅêÉ~ëÉÇ=Äó=~å=~îÉê~ÖÉ=çÑ=NUB=áå=íÜÉ=Ñáå~ëíÉêáÇÉ=Öêçìé=Åçãé~êÉÇ=ïáíÜ ëí~åÇ~êÇK=qÜÉó=ÅçåÅäìÇÉÇ=íÜ~í=~=íÜÉê~éÉìíáÅ=ÉÑÑÉÅí=Éèìáî~äÉåí=íç=íÜ~í ~å=áåÅêÉ~ëÉ=çÑ=NQB=áå=íÜÉ=éä~ÅÉÄç=ÖêçìéK=j~êÄÉêÖÉê=Éí=~ä=xPPz=ÅçãJ çÑ=Ççñ~òçëáå=ëí~åÇ~êÇ=ï~ë=~ÅÜáÉîÉÇ=ïáíÜ=Ççñ~òçëáå=dfqp=ïáíÜ=ÑÉïÉê é~êÉÇ=íÜÉ=äçåÖJíÉêã=ÉÑÑÉÅíë=çÑ=Ñáå~ëíÉêáÇÉ=ER=ãÖLÇ~óF=~åÇ=éä~ÅÉÄç=áå íáíê~íáçå=ëíÉéëI=áå=~=ã~ååÉê=íÜ~í=~ééÉ~êÉÇ=íç=ÄÉ=ÄÉííÉê=íçäÉê~íÉÇ=xOMzK é~íáÉåíë=ïáíÜ=ãçÇÉê~íÉ=ëóãéíçãë=çÑ=_meK=^=OJóÉ~ê=ÇçìÄäÉJÄäáåÇI ê~åÇçãáòÉÇI=éä~ÅÉÄçJÅçåíêçääÉÇ=ãìäíáÅÉåíÉê=ëíìÇó=ï~ë=ÅçåÇìÅíÉÇ=çå Tamsulosin é~íáÉåíë=~ÖÉÇ=RM=íç=TR=óÉ~êëK=lÑ=íÜÉ=PIOTM=ãÉå=ÉåêçääÉÇI=PINSU=ÅçåJ q~ãëìäçëáå=áë=~= JêÉÅÉéíçê=~åí~Öçåáëí=ïáíÜ=ëçãÉ=ëÉäÉÅíáîáíó=Ñçê íêáÄìíÉÇ=Ç~í~=íç=íÜÉ=ë~ÑÉíó=~å~äóëáëK=páÖåáÑáÅ~åíäó=ÖêÉ~íÉê=áãéêçîÉãÉåí αN íÜÉ= =êÉÅÉéíçê=ëìÄíóéÉ=Åçãé~êÉÇ=íç=íÜÉ= =êÉÅÉéíçê=ëìÄíóéÉK ïáíÜ=Ñáå~ëíÉêáÇÉ=Åçãé~êÉÇ=íç=éä~ÅÉÄç=ï~ë=çÄëÉêîÉÇ=~í=NO=~åÇ=OQ αN^ αN_ q~ãëìäçëáå=áë=íÜÉ=ãçëí=éçíÉåí= =~åí~Öçåáëí=áåîÉëíáÖ~íÉÇ=Ñçê=_me=xONzK ãçåíÜë=Ñçê=íçí~ä=ëóãéíçã=ëÅçêÉI=çÄëíêìÅíáîÉ=ëóãéíçã=ëÅçêÉI=ã~ñáã~ä αN q~ãëìäçëáå=áë=ìêçëéÉÅáÑáÅ=~åÇ=ÉñÉêíë=áíë=ÉÑÑÉÅí=éêáã~êáäó=çå=íÜÉ=äçïÉê ìêáå~êó=Ñäçï=ê~íÉ=~åÇ=éêçëí~íÉ=îçäìãÉ=EãÉ~å=JNQKOB=îë=HRKQB=~í=NO ìêáå~êó=íê~ÅíK=fí=áë=ïÉää=~ÄëçêÄÉÇ=~åÇ=Ü~ë=~=Ü~äÑJäáÑÉ=çÑ=R=íç=NM=Ü=xTzK ãçåíÜëI=é=< MKMNX=JNRKPB=îë=HUKVB=~í=OQ=ãçåíÜëI=é=< MKMMNFK=qÜÉó qÜÉ=ÉÑÑáÅ~Åó=~åÇ=ë~ÑÉíó=çÑ=í~ãëìäçëáå=Ü~ë=ÄÉÉå=áåîÉëíáÖ~íÉÇ=áå çÄëÉêîÉÇ=íÜ~í=Ñáå~ëíÉêáÇÉ=Å~ìëÉë=äçåÖJíÉêã=ëóãéíçã~íáÅ=áãéêçîÉãÉåí Ñçìê=ãìäíáÅÉåíÉêI=ê~åÇçãáòÉÇI=ÇçìÄäÉJÄäáåÇI=éä~ÅÉÄçJÅçåíêçääÉÇ=ëíìÇáÉëK ~åÇ=êÉÇìÅÉÇ=íÜÉ=êáëâ=çÑ=~ÅìíÉ=ìêáå~êó=êÉíÉåíáçå=çê=ëìêÖÉêóK iÉéçê=Éí=~ä=Éî~äì~íÉÇ=íÜÉ=äçåÖJíÉêã=ÉÑÑáÅ~Åó=~åÇ=ë~ÑÉíó=çÑ=çåÅÉ=Ç~áäó cáå~ëíÉêáÇÉ=áë=ÖÉåÉê~ääó=ïÉää=íçäÉê~íÉÇI=ïáíÜ=é~íáÉåíë=êÉéçêíáåÖ=ÇÉJ í~ãëìäçëáå=EMKQ=ãÖ=~åÇ=MKU=ãÖF=áå=SNU=é~íáÉåíë=ïáíÜ=_meK=qÜáë=íêá~ä ÅêÉ~ëÉÇ=äáÄáÇç=ESKQB=îë=PKQB=áå=éä~ÅÉÄç=ÖêçìéFI=áãéçíÉåÅÉ=EUKNB=îë ÉñíÉåÇÉÇ=~=NPJïÉÉâI=mÜ~ëÉ=fff=ãìäíáÅÉåíÉê=éä~ÅÉÄçJÅçåíêçääÉÇI=ÇçìÄäÉJ PKTBFI=ÇÉÅêÉ~ëÉÇ=Éà~Åìä~íÉ=EPKTB=îë=MKUBFI=~åÇ=~=YNB=áåÅáÇÉåÅÉ=çÑ ÄäáåÇ=çìíé~íáÉåí=íêá~äK=páÖåáÑáÅ~åí=áãéêçîÉãÉåíë=ïÉêÉ=çÄëÉêîÉÇ=áå=nã~ñ Éà~Åìä~íáçå=ÇáëçêÇÉêëI=ê~ëÜ=~åÇ=ÄêÉ~ëí=Éåä~êÖÉãÉåí=çê=íÉåÇÉêåÉëë=xPOzK Ñçê=ÄçíÜ=í~ãëìäçëáå=Öêçìéë=Äìí=åçí=Ñçê=íÜÉ=éä~ÅÉÄç=ÖêçìéK=q~ãëìäçëáå ~í=ÄçíÜ=Ççë~ÖÉë=ï~ë=ïÉää=íçäÉê~íÉÇ=~ë=ã~áåíÉå~åÅÉ=íÜÉê~éóK=`äáåáÅ~ääó Dutasteride ëáÖåáÑáÅ~åí=çêíÜçëí~íáÅ=ÜóéçíÉåëáçå=ï~ë=åçí=çÄëÉêîÉÇ=xOOzK =aìí~ëíÉêáÇÉI=~=íóéÉ=N=~åÇ=íóéÉ=O=Rα JêÉÇìÅí~ëÉ=áåÜáÄáíçêI=ï~ë ~ééêçîÉÇ=Ñçê=íÜÉ=íêÉ~íãÉåí=çÑ=_me=Äó=íÜÉ=ca^=áå=OMMOK=aìí~ëíÉêáÇÉI ÄÉÅ~ìëÉ=çÑ=áíë=Çì~ä=áåÜáÄáíáçå=çÑ=R JêÉÇìÅí~ëÉI=êÉÇìÅÉë=ëÉêìã Subtypes of α1 antagonists α

NS Current medical treatment for BPH/LUTS

ÇáÜóÇêçíÉëíçëíÉêçåÉ=EaeqF=äÉîÉäë=Äó=[VMB=xPQzK áåÅêÉ~ëÉÇ=ëÉåëáíáîáíó=íç=ãìëÅ~êáåáÅ=êÉÅÉéíçê=ëíáãìä~íáçå=áå=íÜÉ=Ää~ÇJ aÉëÖê~åÇÅÜ~ãéë=Éí=~ä=~ëëÉëëÉÇ=íÜÉ=áãéêçîÉãÉåíë=áå=ëóãéíçãëI ÇÉêë=çÑ=é~êíá~ä=_ll=ê~íëX=ãìëÅ~êáåáÅ=êÉÅÉéíçê=ÄäçÅâ~ÇÉ=Å~ìëÉÇ=~=ëáÖJ nçiI=ÇáëÅçãÑçêí=~åÇ=ë~íáëÑ~Åíáçå=áå=é~íáÉåíë=ïáíÜ=ëóãéíçã~íáÅ=_me åáÑáÅ~åí=ÇÉÅêÉ~ëÉ=áå=íÜÉ=Åçåíê~ÅíáäÉ=êÉëéçåëÉ=áå=~ää=Öêçìéë=xPVzK=få=é~J íêÉ~íÉÇ=ïáíÜ=Çìí~ëíÉêáÇÉ=MKR=ãÖLÇ~ó=Ñçê=OQ=ïÉÉâëK=qÜáë=ï~ë=~ íáÉåíë=ïáíÜ=_meI=ÇÉåÉêî~íáçå=Ü~ë=ÄÉÉå=ÑçìåÇ=ÜáëíçäçÖáÅ~ääó=~åÇ=ÑìåÅJ éêçëéÉÅíáîÉI=ãìäíáÅÉåíÉêI=çéÉåJä~ÄÉä=ëíìÇóK=lÑ=íÜÉ=PSS=é~íáÉåíë íáçå~ääó=áå=îáíêç=xQMIQNzK=fí=Ü~ë=ÄÉÉå=ëìÖÖÉëíÉÇ=íÜ~í=ÇÉíêìëçê=ÜóéÉêëÉåJ ~ëëÉëëÉÇI=TOKRB=~ÅÜáÉîÉÇ=~í=äÉ~ëí=~=PJéçáåí=êÉÇìÅíáçå=áå=fJmpp=~í=OQ ëáíáîáíó=íç=~ÅÉíóäÅÜçäáåÉ=çê=áåÅêÉ~ëÉÇ=ÉäÉÅíêáÅ~ä=ÅçìéäáåÖ=áå=íÜÉëÉ=~êÉ~ë ïÉÉâëX=íÜÉ=fJmpp=ÇÉÅêÉ~ëÉÇ=Ñêçã=NRKP=~í=Ä~ëÉäáåÉ=íç=NMKO=~í=NO=ïÉÉâë Å~ìëÉë=ìåÅççêÇáå~íÉÇ=Åçåíê~Åíáçåë=xQOzK ~åÇ=VKN=~í=OQ=ïÉÉâëK=qÜÉêÉ=ïÉêÉ=ëáÖåáÑáÅ~åí=EéYMKMMNF=ÇÉÅêÉ~ëÉë=áå=~ää ^åíáãìëÅ~êáåáÅë=ÇÉÅêÉ~ëÉ=íÜÉ=Åçåíê~ÅíáäÉ=êÉëéçåëÉ=çÑ=íÜÉ=ÇÉíêìJ íÜÉ=áåÇáîáÇì~ä=fJmpp=áíÉãë=~í=NO=~åÇ=OQ=ïÉÉâëK=qÜÉó=ÅçåÅäìÇÉÇ=íÜ~í ëçê=ãìëÅäÉ=çÑ=l^_=é~íáÉåíëK=få=~=é~íáÉåí=ïáíÜ=_meLirqp=~åÇ=åç=ÉîáJ Çìí~ëíÉêáÇÉ=íêÉ~íãÉåí=Ñçê=OQ=ïÉÉâë=ëáÖåáÑáÅ~åíäó=áãéêçîÉÇ=_me ÇÉåÅÉ=çÑ=_llI=é~êíáÅìä~êäó=áÑ=íÜÉ=éêÉÇçãáå~åí=ëóãéíçãë=~êÉ=íÜçëÉ=çÑ ëóãéíçãëI=nçiI=~åÇ=é~íáÉåí=ÇáëÅçãÑçêí=~åÇ=ë~íáëÑ~Åíáçå=xPRzK=få=íÉêãë l^_I=áí=áë=~ééêçéêá~íÉ=íç=íêÉ~í=íÜÉã=ïáíÜ=~å=~åíáãìëÅ~êáåáÅ=~ÖÉåí=xPzK çÑ=íÜÉ=êÉÇìÅíáçå=çÑ=éêçëí~íÉ=îçäìãÉI=oçÉÜêÄçêå=Éí=~ä=ÅçåÇìÅíÉÇ=~=ëíìÇó póãéíçã=ëÅçêÉë=~åÇ=ìêçÇóå~ãáÅ=ëíìÇáÉë=ÜÉäé=ìë=áå=íÜÉ=ÇáÑÑÉêÉåíá~ä çÑ=QIPOR=ãÉå=EOVRN=ÅçãéäÉíÉÇFI=~åÇ=íÜÉ=íçí~ä=éêçëí~íÉ=~åÇ=íê~åëáíáçå Çá~Öåçëáë=çÑ=ãÉå=ïáíÜ=irqp=xQPzK òçåÉ=îçäìãÉë=ïÉêÉ=êÉÇìÅÉÇ=Äó=~=ãÉ~å=çÑ=ORKTB=~åÇ=OMKQBI=êÉëéÉÅJ íáîÉäó=EéYMKMMNF=xPSzK `lj_fk^qflk=qebo^mv=E Jâobkbodf`=^kq^dlkfpq αN qÜÉ=~ÇîÉêëÉ=ÉÑÑÉÅíë=Ñêçã=Çìí~ëíÉêáÇÉ=~êÉ=ëáãáä~ê=íç=íÜçëÉ=Ñêçã ^ka=^kqfjrp`ôfkf`=^kq^dlkfpqF Ñáå~ëíÉêáÇÉK=få=íÜÉ=ëíìÇó=Äó=aÉëÖê~åÇÅÜ~ãéë=Éí=~äI=íÜÉêÉ=ïÉêÉ=~ÇîÉêëÉ ÉîÉåíë=êÉä~íÉÇ=íç=íÜÉ=ëíìÇó=ÇêìÖ=áå=TT=ENVBF=é~íáÉåíëX=çÑ=íÜÉëÉI=NNB jÉÇáÅ~ä=íêÉ~íãÉåí=íÜ~í=í~êÖÉíë=íÜÉ=éêçëí~íÉ=E JêÉÅÉéíçê=~åí~ÖçJ αN ïÉêÉ=ëÉñì~ä=ÇáëçêÇÉêë=ETB=ÉêÉÅíáäÉ=ÇóëÑìåÅíáçå=EbaFI=QB=ÇÉÅêÉ~ëÉ=áå åáëíë=~åÇ=RαJêÉÇìÅí~ëÉ=áåÜáÄáíçêëF=çÑíÉå=Ñ~áäë=íç=~ääÉîá~íÉ=l^_=ëóãéJ äáÄáÇç=~åÇ=YNB=Éà~Åìä~íçêó=ÇáëçêÇÉêëFI=QB=Ö~ëíêçáåíÉëíáå~ä=ÇáëçêÇÉêë íçãë=~åÇ=ã~ó=åçí=ÄÉ=íÜÉ=ãçëí=~ééêçéêá~íÉ=íÜÉê~éó=Ñçê=ãÉå=ïáíÜ=ëíçêJ Eã~áåäó=~ÄÇçãáå~ä=é~áå=~åÇ=Çá~êêÜÉ~F=~åÇ=OB=ÖóåÉÅçã~ëíá~=EáåÅäìÇáåÖ ~ÖÉ=irqp=xQQzK=jìäíáéäÉ=ëíìÇáÉë=Ü~îÉ=ëÜçïå=íÜ~í=~åíáãìëÅ~êáåáÅ=íÜÉê~éó ã~ãã~êó=íÉåëáçåF=xPRzK ~äçåÉ=çê=áå=ÅçãÄáå~íáçå=ïáíÜ= JêÉÅÉéíçê=~åí~Öçåáëíë=áãéêçîÉë=l^_ αN RαJêÉÇìÅí~ëÉ=áåÜáÄáíçêë=êÉÇìÅÉ=íÜÉ=éêçëí~íÉ=îçäìãÉ=~åÇ=ëç=Å~ìëÉ ëóãéíçãë=áå=ãÉå=ïáíÜ=çê=ïáíÜçìí=_llK=^íÜ~å~ëçéçìäçë=Éí=~ä=éìÄäáëÜÉÇ ~å=É~ëáåÖ=çÑ=áêêáí~íáîÉ=ëóãéíçãëK=qÜÉ=ÉÑÑÉÅí=çÑ=R JêÉÇìÅí~ëÉ=áåÜáÄáíçêë íÜÉ=êÉëìäíë=çÑ=ÅçãÄáå~íáçå=íêÉ~íãÉåí=ïáíÜ=~å= JÄäçÅâÉê=EMKQ=ãÖ α αN çå=ÇÉíêìëçê=ÑìåÅíáçå=áë=ëíáää=íç=ÄÉ=ÇÉíÉêãáåÉÇK í~ãëìäçëáå=çê~ääó=çåÅÉ=~=Ç~óF=éäìë=~å=~åíáÅÜçäáåÉêÖáÅ=EO=ãÖ=íçäíÉêçÇáåÉ çê~ääó=íïáÅÉ=Ç~áäóF=Ñçê=_ll=áå=OMMPK=qÜÉó=ÅçåÅäìÇÉÇ=íÜ~í=íÜÉ=ÅçãÄáå~J `lj_fk^qflk=qebo^mv=E Jâobkbodf`=_il`hbop=H íáçå=íêÉ~íãÉåí=ïáíÜ=~å= =JÄäçÅâÉê=éäìë=~å=~åíáÅÜçäáåÉêÖáÅ=áãéêçîÉë=nçi α αN RαJobar`q^pb=fkef_fqlopF áå=é~íáÉåíë=ïáíÜ=_ll=~åÇ=ÅçåÅçãáí~åí=ÇÉíêìëçê=áåëí~Äáäáíó=xQRzK=qÜÉ éêçéçëÉÇ=ÅçãÄáå~íáçå=íÜÉê~éó=~ééÉ~êë=íç=ÄÉ=~å=ÉÑÑÉÅíáîÉ=~åÇ=êÉä~J qê~Çáíáçå~ääóI=αJ~ÇêÉåÉêÖáÅ=ÄäçÅâÉêë=~êÉ=ìëÉÇ=Ñçê=êÉäáÉÑ=çÑ=irqp=~ë íáîÉäó=ë~ÑÉ=íêÉ~íãÉåí=çéíáçå=Ñçê=é~íáÉåíë=ïáíÜ=_ll=~åÇ=ÇÉíêìëçê=áåëí~ÄáäáíóK ~=êÉëìäí=çÑ=_me=~åÇ=~êÉ=âåçïå=Ñçê=íÜÉáê=èìáÅâ=çåëÉí=çÑ=~ÅíáçåK=RαJêÉJ páãáä~ê=êÉëìäíë=ïÉêÉ=êÉéçêíÉÇ=Äó=ëÉîÉê~ä=çíÜÉê=ëíìÇáÉëK=iÉÉ=Éí=~ä ÇìÅí~ëÉ=áåÜáÄáíçêë=Ü~îÉ=éêçîÉå=ìëÉÑìä=Ñçê=íÜÉ=éêÉîÉåíáçå=çÑ=_me=éêçJ Éî~äì~íÉÇ=íÜÉ=ÉÑÑáÅ~Åó=~åÇ=ë~ÑÉíó=çÑ=~=íÜÉê~éÉìíáÅ=ãçÇ~äáíó=áåîçäîáåÖ ÖêÉëëáçå=Äó=êÉÇìÅáåÖ=éêçëí~íÉ=îçäìãÉK=oÉÅÉåí=ëíìÇáÉë=Ü~îÉ=ëÜçïå éêçéáîÉêáåÉ=ÅçãÄáåÉÇ=ïáíÜ=Ççñ~òçëáå=áå=é~íáÉåíë=ïáíÜ=l^_=~åÇ=ÄÉåáÖå íÜ~í=íÜÉ=ÅçãÄáå~íáçå=çÑ=~å=αJ~ÇêÉåÉêÖáÅ=ÄäçÅâÉê=~åÇ=~=RαJêÉÇìÅí~ëÉ éêçëí~íáÅ=çÄëíêìÅíáçåK=^=íçí~ä=çÑ=ONN=ãÉå=RM=óÉ~êë=çÑ=~ÖÉ=çê=çäÇÉê=ïáíÜ áåÜáÄáíçê=Ü~ë=ëáÖåáÑáÅ~åíäó=ÄÉííÉê=ÉÑÑáÅ~Åó=íÜ~å=ÉáíÜÉê=ÇêìÖ=~äçåÉ=çê=éä~J l^_=ëóãéíçãë=~åÇ=ìêçÇóå~ãáÅ~ääó=éêçîÉå=_ll=ïÉêÉ=ê~åÇçãáòÉÇ ÅÉÄç=xPTzK áåíç=O=Öêçìéë=Ñçê=~å=UJïÉÉâ=íêÉ~íãÉåíW=Öêçìé=N=J=Ççñ~òçëáå=EQ=ãÖ=çåÅÉ jÅ`çååÉää=Éí=~ä=éìÄäáëÜÉÇ=íÜÉáê=êÉéçêí=çå=ÅçãÄáå~íáçå=íÜÉê~éó=áå Ç~áäóF=çåäóI=Öêçìé=O=JéêçéáîÉêáåÉ=ÜóÇêçÅÜäçêáÇÉ=EOM=ãÖ=çåÅÉ=Ç~áäóF=éäìë OMMPK=qÜÉó=ÅçåÇìÅíÉÇ=~=äçåÖJíÉêã=ÇçìÄäÉJÄäáåÇ=íêá~ä=EãÉ~å=ÑçääçïJìé Ççñ~òçëáåK=m~íáÉåí=ë~íáëÑ~Åíáçå=ê~íÉë=ïÉêÉ=ÑçìåÇ=íç=ÄÉ=ëáÖåáÑáÅ~åíäó=ÜáÖÜÉê QKR=óÉ~êëF=áåîçäîáåÖ=PIMQT=ãÉå=íç=Åçãé~êÉ=íÜÉ=ÉÑÑÉÅíë=çÑ=éä~ÅÉÄçI áå=Öêçìé=O=íÜ~å=áå=Öêçìé=NK=qÜáë=ëíìÇó=êÉîÉ~äë=íÜ~í=ÅçãÄáå~íáçå=íÜÉê~éóI Ççñ~òçëáåI=Ñáå~ëíÉêáÇÉ=~åÇ=ÅçãÄáå~íáçå=íÜÉê~éó=çå=íÜÉ=ÅäáåáÅ~ä=éêçJ ÅçåëáëíáåÖ=çÑ= J~ÇêÉåçêÉÅÉéíçê=~åí~Öçåáëíë=ïáíÜ=~åíáãìëÅ~êáåáÅëI=êÉéJ αN ÖêÉëëáçå=çÑ=_meK=qÜÉ=êÉÇìÅíáçå=áå=êáëâ=~ëëçÅá~íÉÇ=ïáíÜ=ÅçãÄáå~íáçå êÉëÉåíë=~å=ÉÑÑÉÅíáîÉ=~åÇ=êÉä~íáîÉäó=ë~ÑÉ=íêÉ~íãÉåí=ãçÇ~äáíó=Ñçê=ëÉäÉÅíÉÇ íÜÉê~éó=ï~ë=ëáÖåáÑáÅ~åíäó=ÖêÉ~íÉê=íÜ~å=íÜ~í=~ëëçÅá~íÉÇ=ïáíÜ=Ççñ~òçëáå é~íáÉåíë=ïáíÜ=l^_=ÅçÉñáëíáåÖ=ïáíÜ=ÄÉåáÖå=éêçëí~íáÅ=çÄëíêìÅíáçå=xQSzK çê=Ñáå~ëíÉêáÇÉ=~äçåÉK=qÜÉ=êáëâë=çÑ=~ÅìíÉ=ìêáå~êó=êÉíÉåíáçå=~åÇ=íÜÉ=åÉÉÇ Ñçê=áåî~ëáîÉ=íÜÉê~éó=ïÉêÉ=ëáÖåáÑáÅ~åíäó=êÉÇìÅÉÇ=Äó=ÅçãÄáå~íáçå=íÜÉê~éó melpmelafbpqbo^pbJR=EmabJRF=fkef_fqlop ~åÇ=Ñáå~ëíÉêáÇÉ=Äìí=åçí=Äó=Ççñ~òçëáåK=açñ~òçëáåI=Ñáå~ëíÉêáÇÉ=~åÇ=ÅçãJ Äáå~íáçå=íÜÉê~éó=É~ÅÜ=êÉëìäíÉÇ=áå=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåí=áå=ëóãéíçã qÜÉ=ê~íáçå~äÉ=Ñçê=ìëáåÖ=mabJR=áåÜáÄáíçêë=Ñçê=íÜÉ=íêÉ~íãÉåí=çÑ=_me ëÅçêÉëI=ïáíÜ=ÅçãÄáå~íáçå=íÜÉê~éó=ÄÉáåÖ=ëìéÉêáçê=íç=ÄçíÜ=Ççñ~òçëáå é~íáÉåíë=çêáÖáå~íÉë=Ñêçã=íÜÉ=ÑçääçïáåÖ=íÜêÉÉ=çÄëÉêî~íáçåëW=ÑáêëíI=íÜÉ=éêÉî~J ~åÇ=Ñáå~ëíÉêáÇÉ=~äçåÉK=qÜáë=ëíìÇó=ÅçåÅäìÇÉÇ=íÜ~í=íÜÉ=ÅçãÄáå~íáçå äÉåÅÉ=çÑ=irqpI=_me=~åÇ=ba=áåÅêÉ~ëÉë=ïáíÜ=~ÖÉX=ëÉÅçåÇI=mabJR=áåÜáÄáJ íÜÉê~éó=~åÇ=Ñáå~ëíÉêáÇÉ=~äçåÉ=êÉÇìÅÉÇ=íÜÉ=äçåÖJíÉêã=êáëâ=çÑ=~ÅìíÉ=ìêáJ íáçå=ãÉÇá~íÉë=ëãççíÜ=ãìëÅäÉ=êÉä~ñ~íáçå=áå=íÜÉ=äçïÉê=ìêáå~êó=íê~ÅíX=~åÇ å~êó=êÉíÉåíáçå=~åÇ=íÜÉ=åÉÉÇ=Ñçê=áåî~ëáîÉ=íÜÉê~éó=xPUzK íÜáêÇI=É~êäó=ÅäáåáÅ~ä=ÉîáÇÉåÅÉ=ÇÉãçåëíê~íÉë=íÜ~í=mabJR=áåÜáÄáíçêë=~êÉ ëìÅÅÉëëÑìä=áå=íêÉ~íáåÖ=irqp=~åÇ=ba=xQTzK ^kqfjrp`ôfkf`p qÜÉ=êçäÉ=çÑ=mabJRë=Ñçê=íêÉ~íáåÖ=_me=áë=éççêäó=ìåÇÉêëíççÇW êÉéçêíÉÇäóI=î~êáçìë=mab=áëçÉåòóãÉë=~êÉ=ÉñéêÉëëÉÇ=áå=íÜÉ=éêçëí~íÉ=~åÇ qÜÉ=áåÅáÇÉåÅÉ=çÑ=çîÉê~ÅíáîÉ=Ää~ÇÇÉê=El^_F=~ëëçÅá~íÉÇ=ïáíÜ=Ää~ÇJ íÜÉêÉ=~êÉ=ëçãÉ=ÅäìÉë=íÜ~í=ìåëéÉÅáÑáÅ=mab=áåÜáÄáíáçå=Å~å=êÉä~ñ=Üìã~å ÇÉê=çìíäÉí=çÄëíêìÅíáçå=E_llF=áë=PMBJSMB=KqÜÉ=ëóãéíçãë=çÑ=íÜÉ=íïç éêçëí~íÉ=íáëëìÉ=xQUzK=qáåÉä=Éí=~ä=Éî~äì~íÉÇ=íÜÉ=éçíÉåíá~ä=çÑ=ëáäÇÉå~ÑáäI ~êÉ=ëáãáä~ê=~åÇ=çîÉêä~ééáåÖK=aÉíêìëçê=çîÉê~Åíáîáíó=Ü~ë=ÄÉÉå=ãçÇÉäÉÇ î~êÇÉå~Ñáä=~åÇ=í~Ç~ä~ÑáäI=~ää=mabJR=áåÜáÄáíçêë=ìëÉÇ=Ñçê=íêÉ~íáåÖ=baI=_me Äó=é~êíá~ä=_ll=áå=ëÉîÉê~ä=~åáã~ä=ëéÉÅáÉëK=pÅÜêçÇÉê=Éí=~ä=çÄëÉêîÉÇ ~åÇ=irqp=áå=~åáã~ä=ëíìÇáÉëK=qÜÉ=ãok^=ÉñéêÉëëáçå=çÑ=íÜÉ=mabJR=ï~ë

NT C. L. Chou

ÇÉíÉêãáåÉÇ=áå=ê~í=äçïÉê=ìêáå~êó=íê~Åí=íáëëìÉëK=qÜÉ=ÜáÖÜÉëí=mabJR=ãok^ placebo-controlled study. Br J Urol 1987; 60:136-142. ÉñéêÉëëáçå=ï~ë=áå=íÜÉ=Ää~ÇÇÉêI=ÑçääçïÉÇ=Äó=íÜÉ=ìêÉíÜê~=~åÇ=éêçëí~íÉK 10. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of re- mabJR=áåÜáÄáíçêë=ÇçëÉJÇÉéÉåÇÉåíäó=êÉÇìÅÉÇ=íÜÉ=Åçåíê~Åíáçå=çÑ=íÜÉ=áëçJ combinant alpha 1-adrenoceptors to characterize subtype selectiv- ä~íÉÇ=Ää~ÇÇÉêI=ìêÉíÜê~ä=~åÇ=éêçëí~íÉ=ëíêáéëK=qÜÉáê=êÉëìäíë=ëÜçï=íÜ~í=mabJ ity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288:201-207. R=áåÜáÄáíçêë=áåÇìÅÉÇ=ëáÖåáÑáÅ~åí=êÉä~ñ~íáçå=çÑ=íÜÉëÉ=íáëëìÉë=~åÇ=êÉÇìÅÉÇ 11. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, íÜÉ=áêêáí~íáîÉ=ëóãéíçãë=çÑ=_meLirqp=áå=îáîç=xQVzK Naylor AM: Evaluation of the pharmacological selectivity profile of qÜÉ=ÉÑÑáÅ~Åó=çÑ=ëáäÇÉå~Ñáä=Ñçê=ba=~åÇ=irqp=áå=ãÉå=ï~ë=Éî~äì~íÉÇ alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: Äó=jÅs~êó=Éí=~äK=qÜáë=ï~ë=~=NOJïÉÉâI=ÇçìÄäÉJÄäáåÇI=éä~ÅÉÄçJÅçåíêçääÉÇ Binding, functional and in vivo studies. Br J Pharmacol 1996; 118: ëíìÇó=çÑ=ëáäÇÉå~Ñáä=áå=ãÉå=QR=óÉ~êë=çÑ=~ÖÉ=çê=çäÇÉê=ïÜç=ëÅçêÉÇ=OR=çê 871-878. äÉëë=çå=íÜÉ=ÉêÉÅíáäÉ=ÑìåÅíáçå=Ççã~áå=çÑ=íÜÉ=fåíÉêå~íáçå~ä=fåÇÉñ=çÑ=bêÉÅJ 12. De Nunzio C, Franco G, Leonardo C, Trucchi A, Tubaro A, Laurenti íáäÉ=cìåÅíáçå=~åÇ=NO=çê=ãçêÉ=çå=íÜÉ=fJmppK=qÜÉ=NUV=ãÉå=êÉÅÉáîáåÖ C: Effect of Once-Daily Alfuzosin on Urinary Symptoms and Flow Rate in Benign Prostatic Hyperplasia: A 24-Hour Home-Uroflowmetry ëáäÇÉå~Ñáä=Ü~Ç=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåíë=áå=ÉêÉÅíáäÉ=ÑìåÅíáçå=Ççã~áå Evaluation. Clin Drug Investig 2005; 25:359-365. ëÅçêÉë=Åçãé~êÉÇ=íç=íÜÉ=NUM=ãÉå=çå=éä~ÅÉÄçK=qÜÉ=êÉëìäíë=ëÜçïÉÇ=íÜ~í 13. Kyncl JJ: Pharmacology of terazosin: An alpha 1-selective blocker. ãÉå=çå=ëáäÇÉå~Ñáä=Ü~Ç=ëáÖåáÑáÅ~åí=áãéêçîÉãÉåíë=áå=fJmpp=EéYMKMMMNFI J Clin Pharmacol 1993; 33:878-883. _ÉåáÖå=mêçëí~íáÅ=eóéÉêéä~ëá~=fãé~Åí=fåÇÉñ=EéYMKMMMNF=~åÇ=ãÉ~å=fJ 14. Wilde MI, Fitton A, Sorkin EM, Terazosin: A review of its pharmaco- mpp=nçi=ëÅçêÉë=Åçãé~êÉÇ=íç=íÜçëÉ=êÉÅÉáîáåÖ=éä~ÅÉÄçK=fãéêçîÉÇ=ba dynamic and pharmacokinetic properties, and therapeutic potential ~åÇ=irqp=ïÉêÉ=çÄëÉêîÉÇ=áå=íÜÉ=é~íáÉåíë=êÉÅÉáîáåÖ=ëáäÇÉå~Ñáä=xRMzK in benign prostatic hyperplasia. Drugs Aging 1993; 3:258-277. eçïÉîÉêI=íÜÉ=ä~Åâ=çÑ=ÉÑÑÉÅí=çå=ìêáå~êó=Ñäçï=ê~íÉë=ã~ó=ãÉ~å=íÜ~í=~ 15. Roehrborn CG, Oesterling JE, Auerbach S, et al: The Hytrin Com- munity Assessment Trial study: A one-year study of terazosin ver- åÉï=Ä~ëáÅ=é~íÜçéÜóëáçäçÖó=é~ê~ÇáÖã=áë=åÉÉÇÉÇ=íç=Éñéä~áå=íÜÉ=ÉíáçäJ sus placebo in the treatment of men with symptomatic benign pro- çÖó=çÑ=irqp=xRMzK static hyperplasia. HYCAT Investigator Group. Urology 1996; 47: 159-168. `lk`irpflkp 16. Elhilali MM, Ramsey EW, Barkin J, et al: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and _çíÜ=_me=~åÇ=irqp=~êÉ=Åçããçå=áå=íÜÉ=ÉäÇÉêäó=ã~äÉ=éçéìä~íáçåK efficacy of terazosin in the treatment of benign prostatic hyperplasia. táíÜ=ÄÉííÉê=ìåÇÉêëí~åÇáåÖ=çÑ=íÜÉ=å~íìê~ä=Üáëíçêó=~åÇ=é~íÜçéÜóëáçäçÖó Urology 1996; 47:335-342. 17. Lepor H, Auerbach S, Puras-Baez A, et al: A randomized, placebo- çÑ=_me=~åÇ=irqpI===ãÉÇáÅ~ä=íÜÉê~éó=éä~óë=~=ãçêÉ=áãéçêí~åí=êçäÉ=íÜ~å controlled multicenter study of the efficacy and safety of terazosin ÄÉÑçêÉK=_çíÜ= JÄäçÅâÉêë=~åÇ=R JêÉÇìÅí~ëÉ=áåÜáÄáíçêë=Ü~îÉ=ÄÉÉå=ëÜçïå αN α in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: íç=ÄÉ=ÉÑÑÉÅíáîÉ=áå=ÅäáåáÅ~ä=íêá~äëK=`çãÄáå~íáçå=íêÉ~íãÉåí=çÑ= JÄäçÅâÉêë αN 1467-1474. éäìë=~åíáãìëÅ~êáåáÅë=~ééÉ~êë=íç=ÄÉ=~å=ÉÑÑÉÅíáîÉ=~åÇ=êÉä~íáîÉäó=ë~ÑÉ=íêÉ~íJ 18. Os I, Stokke HP: Effects of doxazosin in the gastrointestinal thera- ãÉåí=çéíáçå=Ñçê=ëÉäÉÅíÉÇ=é~íáÉåíë=ïáíÜ=l^_=ÅçÉñáëíáåÖ=ïáíÜ=ÄÉåáÖå=éêçJ peutic system formulation versus doxazosin standard and placebo ëí~íáÅ=çÄëíêìÅíáçåK=`~êÉÑìä=ÜáëíçêóJí~âáåÖ=~åÇ=ÜáÖÜ=èì~äáíó=ìêçÇóå~ãáÅ in mild-to-moderate hypertension. Doxazosin Investigators' Study ëíìÇáÉë=ÜÉäé=ìë=íç=ëÉäÉÅí=éêçéÉê=ëáåÖäÉ=çê=ÅçãÄáå~íáçå=ãÉÇáÅ~ä=íÜÉê~éó Group. J Cardiovasc Pharmacol 1999; 33:791-797. 19. Goldsmith DR, Plosker GL: Doxazosin gastrointestinal therapeutic Ñçê=_me=~åÇLçê=irqpK system: A review of its use in benign prostatic hyperplasia. Drugs 2005; 65:2037-2047. obcbobk`bp 20. Andersen M, Dahlstrand C, Hoye K: Double-blind trial of the doxazosin in the gastrointestinal therapeutic system, doxazosin 1. Chapple CR, Smith D: The pathophysiological changes in the blad- standard, and placebo in patients with benign prostatic hyperplasia. der obstructed by benign prostatic hyperplasia. Br J Urol 1994; 73: Eur Urol 2000; 38:400-409. 117-123. 21. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of re- combinant alpha-1 adrenoceptors to characterize subtype selectiv- 2. Schwinn DA, Price DT, Narayan P: [alpha]1-Adrenoceptor Subtype Selectivity and Lower Urinary Tract Symptoms. Mayo Clin Proc 2004; ity of drugs for the treatment of prostatic hypertrophy. Eur J 79:1423-1434. Pharmacol 1995; 288:201-207. 3. Chapple RC: Pharmacological therapy of benign prostatic hyper- 22. Lepor H: Phase III multicenter placebo-controlled study of tamsulosin plasia/lower urinary tract symptoms: An overview for the practicing in benign prostatic hyperplasia. Tamsulosin Investigator Group. clinician. BJU Int 2004; 94:738-744. Urology 1998; 51:892-900. 23. Michelotti GA, Price DT, Schwinn DH: Alpha-1 adrenergic receptor 4. Chou EC, Capello SA, Levin RM, Longhurst PA: Excitatory α1-adre- regulation: Basic science and clinical implications. Pharmacol Ther nergic receptors predominate over inhibitory α1-receptors in rabbit dorsal detrusor. J Urol 2003; 170:2503-2507. 2000; 88:281-309. 5. Lepor H, Lowe FC: Evaluation and Nonsurgical Management of Be- 24. Djavan B, Marberger M: A meta-analysis on the efficacy and toler- nign Prostatic Hyperplasia. In: Walsh PC, Retic AB, eds. Campbell's ability of alpha1-adrenoceptor antagonists in patients with lower Urology, 8th ed, Philadelphia, Saunders, 2002. urinary tract symptoms suggestive of benign prostatic obstruction. 6. Caine M, Pfau A, Perlberg S: The use of alpha-adrenergic blockers Eur Urol 1999; 36:1-13. in benign prostatic obstruction. Br J Urol 1976; 48:255-263. 25. Guthrie RM, Siegel RL: A multicenter, community-based study of 7. Garg G, Singh D, Saraf S, Saraf S: Management of benign prostate doxazosin in the treatment of concomitant hypertension and symp- hyperplasia: An overview of alpha-adrenergic antagonist. Biol Pharm tomatic benign prostatic hyperplasia: The Hypertension and BPH Bull 2006; 29:1554-1558. Intervention Trial (HABIT). Clin Ther 1999; 21:1732-1748. 8. Hedlund H, Andersson KE, Ek A: Effects of prazosin in patients 26. Kumar VI, Dewan S: Alpha adrenergic blockers in the treatment of with benign prostatic obstruction. J Urol 1983; 130:275-278. benign hyperplasia of the prostate. Int Urol Nephrol 2000; 32:67- 9. Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan 71. M, Milroy EJ: Prazosin in the treatment of prostatic obstruction. A

NU Current medical treatment for BPH/LUTS

27. Michel MC, Bressel HU, Mehlburger L, Goepel M: Tamsulosin: Real 39. Schroder A, Uvelius B, Newgreen D, Andersson KE: Bladder life clinical experience in 19,365 patients. Eur Urol 1998; 34(Suppl overactivity in mice after 1 week of outlet obstruction. Mainly affer- 2):37-45. ent dysfunction? J Urol 2003; 170:1017-1021. 28. Forray C, Bard JA, Wetzel JM, et al: The alpha 1-adrenergic recep- 40. Levin RM, Haugaard N, O'Connor L, et al: Obstructive response of tor that mediates smooth muscle contraction in human prostate has human bladder to BPH vs rabbit bladder response to partial outlet the pharmacological properties of the cloned human alpha 1c obstruction: A direct comparison. Neurourol Urodyn 2000; 19:609- subtype. Mol Pharmacol 1994; 45:703-708. 629. 29. Blue D, Zinner N, Grino P, Crager M, Ford A: RO700004, a selec- 41. Gosling JA, Gilpin SA, Dixon JS, Gilpin CJ: Decrease in the auto-

tive α1A-adrenoceptor antagonist, does not improve lower urinary nomic innervation of human detrusor muscle in outflow obstruction. tract symptoms in men with benign prostatic hyperplasia. J Urol J Urol 1986; 136:501-504. suppl 2002; 167:265. 42. Mills IW, Greenland JE, McMurray G, et al: Studies of the patho-

30. Gu B, Reiter JP, Schwinn DA, et al: Effects of α1-adrenergic recep- physiology of idiopathic detrusor instability: The physiological prop- tor subtype selective antagonists on lower urinary tract function in erties of the detrusor smooth muscle and its pattern of innervation. rats with bladder outlet obstruction. J Urol 2004; 172:758-762. J Urol 2000; 163:646-651. 31. Li X, Chen C, Singh SM, Labrie F, Labire F: The enzyme and inhibi- 43. De la Rosette JJ, Witjes WP, Schafer W, et al: Relationships be- tors of 4-ene-oxosteroid 5 alpha-oxidoreductase. Steroids 1995; 60: tween lower urinary tract symptoms and bladder outlet obstruction: 430-441. Results from the ICS-''BPH'' study. Neurourol Urodyn 1998;17:99- 32. McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride 108. on the risk of acute urinary retention and the need for surgical treat- 44. Chapple CR, Roehrborn CG: A shifted paradigm for the further ment among men with benign prostatic hyperplasia. Finasteride understanding, evaluation, and treatment of lower urinary tract symp- Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; toms in men: Focus on the bladder. Eur Urol 2006; 49:651-658. 338:557-563. 45. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis

33. Marberger MJ: Long-term effects of finasteride in patients with be- P, Barbalias G: Combination treatment with an α1-blocker plus an nign prostatic hyperplasia: A double-blind, placebo-controlled, anticholinergic for bladder outlet obstruction: A prospective, multicenter study. PROWESS Study Group. Urology 1998; 51:677- randomized, controlled study J Urol 2003; 169:2253 -2256. 686. 46. Lee KS, Choo MS, Kim DY, et al: Combination treatment with 34. Roehrborn CG, Boyle P, Nickel JC, et al: Efficacy and safety of a propiverine hydrochloride plus doxazosin controlled release gas- dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in trointestinal therapeutic system formulation for overactive bladder men with benign prostatic hyperplasia. Urology 2002; 60:434-441. and coexisting benign prostatic obstruction: A prospective, 35. Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A: randomized, controlled multicenter study. J Urol 2005; 174:1334- Effect of dutasteride on the symptoms of benign prostatic 1338. hyperplasia, and patient quality of life and discomfort, in clinical 47. Gonzalez RR, Kaplan SA: Tadalafil for the treatment of lower uri- practice. BJU Int 2006; 98:83-88. nary tract symptoms in men with benign prostatic hyperplasia. Ex- 36. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G: Efficacy pert Opin Drug Metabol Toxicol 2006; 2:609-617. and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 48. Drescher P, Eckert RE, Madsen PO: Smooth muscle contractility in (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; prostatic hyperplasia: Role of cyclic adenosine monophosphate. 60:434-441. Prostate 1994; 25:76-80. 37. Sandhu JS, Vaughan ED, Jr: Combination therapy for the pharma- 49. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P: Pre-clinical evidence cological management of benign prostatic hyperplasia: Rationale for the use of phosphodiesterase-5 inhibitors for treating benign and treatment options. Drugs Aging 2005; 22:901-912. prostatic hyperplasia and lower urinary tract symptoms BJU Int 2006; 38. McConnell JD, Roehrborn CG, Bautista OM, et al: Medical Therapy 98:1259-1263. of Prostatic Symptoms (MTOPS) Research Group. The long-term 50. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ. van den effect of doxazosin, finasteride, and combination therapy on the clini- Ende G: Sildenafil citrate improves erectile function and urinary cal progression of benign prostatic hyperplasia. New Engl J Med symptoms in men with erectile dysfunction and lower urinary tract 2003; 349:2387-2398. symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007; 177:1071-1077.